Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 5 of 95, showing 5 Applications out of 474 total, starting on record 21, ending on 25

# Protocol No Study Title Investigator(s) & Site(s)

21.

ECCT/24/04/01   B/F/TAF to DTG/3TC Switch Stud
    Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Kenyatta National Hospital (Nairobi City county)
 
View

22.

ECCT/24/03/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Prof Walter Godfrey Jaoko
Site(s) in Kenya
1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
View

23.

ECCT/24/03/06   PHOENIx MDR-TB)
    Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)   
Principal Investigator(s)
1. Dr Lucy Chepkurui Koech KOECH
Site(s) in Kenya
1. Kenya medical Research Institute/ Walter Reed Project (Kericho county)
2. Moi university clinic research Centre (Uasin Gishu county)
 
View

24.

ECCT/24/03/05   221163 PALISADE
    Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition   
Principal Investigator(s)
1. Grace Mboya
Site(s) in Kenya
KEMRI Kisumu Clinical Research Site
 
View

25.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
View